Glycemic instability in type 1 diabetic patients: Possible role of ketosis or ketoacidosis at onset of diabetes

Diabetes Research and Clinical Practice

Volumn 81, Issue 2, 2008, Pages 190-195

  Sassa, Mariko ^a   Yamada, Yuichiro ^b   Hosokawa, Masaya ^a   Fukuda, Kazuhito ^a   Fujimoto, Shimpei ^a   Toyoda, Kentaro ^a   Tsukiyama, Katsushi ^a   Seino, Yutaka ^c   Inagaki, Nobuya ^a  

^a KYOTO UNIVERSITY   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANSAI DENRYOKU HOSPITAL   (Japan)

Author keywords

C peptide; Glycemic instability; Ketosis; Type 1 diabetes

Indexed keywords

C PEPTIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL FEATURE; CRITERION VARIABLE; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; GLYCEMIC INSTABILITY; HORMONE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; FEMALE; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED;

EID: 47649114309     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.04.009     Document Type: Article

References (32)

1. Kawasaki E., Matsuura N., and Eguchi K. Type 1 diabetes in Japan. Diabetologia 49 (2006) 828-836
2. Stenström G., Gottsäter A., Bakhtadze E., Berger B., and Sundkvist G. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes 54 Suppl. 2 (2005) S68-S72
3. Imagawa A., Hanafusa T., Miyagawa J., and Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N. Engl. J. Med. 342 (2000) 301-307
4. Karvonen M., Viik-Kajander M., Moltchanova E., Libman I., LaPorte R., and Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 23 (2000) 1516-1526
5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Report of the expert committee on the diagnosis and classification of diabetes mellitus, Diabetes Care 26 (Suppl. 1) (2003) S5-S20.
6. 1c in the Diabetes Control and Complications Trial. Diabetes Care 25 (2002) 275-278
7. Sassa M., Fukuda K., Fujimoto S., Toyoda K., Fujita Y., Matsumoto S., et al. A single transplantation of the islets can produce glycemic stability and reduction of basal insulin requirement. Diabetes Res. Clin. Pract. 73 (2006) 235-240
8. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.-P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 (2006) 1681-1687
9. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 54 (2005) 1-7
10. Gill G.V. The spectrum of brittle diabetes. J. R. Soc. Med. 85 (1992) 259-261
11. Allen K.V., and Frier B.M. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr. Pract. 9 (2003) 530-543
12. Service F.J., Molnar G.D., Rosevear J.W., Ackerman E., Gatewood L.C., and Taylor W.F. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19 (1970) 644-655
13. Schlichtkrull J., Munck O., and Jersild M. The M-value, an index of blood-sugar control in diabetics. Acta Med. Scand. 177 (1965) 95-102
14. Toso C., Baertschiger R., Morel P., Bosco D., Armanet M., Wojtusciszyn A., et al. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. Am. J. Transplant. 6 (2006) 1049-1058
15. Kishimoto M., Yamasaki Y., Kubota M., Arai K., Morishima T., Kawamori R., et al. 1,5-Anhydro-d-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18 (1995) 1156-1159
16. Mirouze J., Satingher A., Sany C., and Jaffiol C. Insulin efficiency coefficient. M coefficient of Schlichtkrull corrected and simplified by the continuous blood glucose recording technic. Diabete 11 (1963) 267-273
17. J. Schlichtkrull, J. Funder, O. Munck, Clinical evaluation of a new insulin preparation, 4e Congrès de la Fédération Internationale du Diabète, Fédération Internationale du Diabète, Genève, 1961, pp. 303-305.
18. Holleman F., Schmitt H., Rottiers R., Rees A., Symanowski S., and Anderson J.H. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 20 (1997) 1827-1832
19. Japan Diabetes Society, Treatment Guide for Diabetes, Bunkodo, 2007.
20. Tsurumi H., Kondoh H., Horii T., and Igari J. Fundamental evaluation of AIA-PACK C-peptide. J. Clin. Lab. Inst. Reag. 19 (1996) 885-892
21. Fujimoto J., Hirota M., Hata M., Kondo M., and Shima K. Normal reference values and prediction equations of autonomic nerve functions based on variations in the R-R interval in electrocardiographs. J. Japan Diab. Soc. 30 (1987) 167-173
22. Reynolds C., Molnar G..D., Horwitz D.L., Rubenstein A.H., Taylor W.F., and Jiang N.-S. Abnormalities of endogenous glucagon and insulin in unstable diabetes. Diabetes 26 (1977) 36-45
23. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann. Intern. Med. 128 (1998) 517-523
24. Dinneen S., Alzaid A., Turk D., and Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38 (1995) 337-343
25. Sjöbom N.C., Adamson U., and Lins P.-E. The prevalence of impaired glucose counter-regulation during an insulin-infusion test in insulin-treated diabetic patients prone to severe hypoglycaemia. Diabetologia 32 (1989) 818-825
26. Tattersall R., Gregory R., Selby C., Kerr D., and Heller S. Course of brittle diabetes: 12 year follow up. BMJ 302 (1991) 1240-1243
27. Schade D.S., Drumm D.A., Duckworth W.C., and Eaton R.P. The etiology of incapacitating, brittle diabetes. Diabetes Care 8 (1985) 12-20
28. Morris A.D., Boyle D.I., McMahon A.D., Greene S.A., MacDonald T.M., and Newton R.W. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 350 (1997) 1505-1510
29. Schade D.S., and Eaton R.P. Pathogenesis of diabetic ketoacidosis: a reappraisal. Diabetes Care 2 (1979) 296-306
30. Müller W.A., Faloona G.R., and Unger R.H. Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am. J. Med. 54 (1973) 52-57
31. Salehi A., Vieira E., and Gylfe E. Paradoxical stimulation of glucagon secretion by high glucose concentrations. Diabetes 55 (2006) 2318-2323
32. Harrison L.C., Honeyman M.C., DeAizpurua H.J., Schmidli R.S., Colman P.G., Tait B.D., et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 341 (1993) 1365-1369